Login
$HALO
$96.50 -$3.77 (3.76%) Live

$HALO 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Total Revenue of $1.860 - $1.925 billion, YOY Growth of 33% - 38%

30 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

(d) On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Mr. Daly was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders ...

22 Sep 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

INDENTURE, dated as of September 22, 2026, between Halozyme Therapeutics, Inc., a Delaware corporation, as issuer (the “Company”), and The Bank of New York Mellon Trust Company, N.A., not in its individual capacity but solely as trustee,...

18 Sep 2026 8-K: Other Events

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033

16 Sep 2026 8-K: Other Events

SAN DIEGO, CA, September 16, 2026 — Halozyme Therapeutics, Inc. (Nasdaq: HALO) (“Halozyme” or the “Company”), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amo...

18 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

(d) On August 14, 2026, Dannielle Appelhans was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Ms. Appelhans was elected to the class of directors with terms ending at the Company’s annual meeting of st...

06 Aug 2026 8-K: Results of Operations and Financial Condition

Total Revenue of $1.835 - $1.910 billion, YOY Growth of 31% - 37%

02 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

(b) On June 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced an update to its senior management structure. The company also announced the departure of Cortney Caudill as the Company’s Senior Vice President, Chief Operating...

11 May 2026 8-K: Results of Operations and Financial Condition

Total Revenue of $1.710 - $1.810 billion, YOY Growth of 22% - 30%

07 May 2026 8-K: Submission of Matters to a Vote of Security Holders

On May 5, 2026, Halozyme Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders. Of the 118,474,300 shares of the Company's common stock outstanding as of the record date, 104,138,244 shares were represented at the an...

30 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

SAN DIEGO, April 30, 2026 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) today announced the appointment of Darren Snellgrove as Chief Financial Officer (CFO), effective June 8, 2026.

24 Apr 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

1.1 Place of Meetings. All meetings of stockholders shall be held at such place (if any) within or without the State of Delaware as may be designated from time to time by the Board of Directors (the “Board”).

12 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

SAN DIEGO, March 12, 2026 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) today announced that David Ramsay has been appointed Interim Chief Financial Officer (CFO), effective March 23, 2026. Mr. Ramsay will o...

17 Feb 2026 8-K: Results of Operations and Financial Condition

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion

28 Jan 2026 8-K: Results of Operations and Financial Condition

- Total Revenue of $1,385 - $1,400 million, YoY Growth of 36% to 38%1

09 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

(e) On December 4, 2025, the Compensation Committee of the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”) approved a performance-based restricted stock unit grant (the “PSU Grant”) for Dr. Helen Torley, Chief Executive...

08 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

(d) On December 4, 2025, James Lang was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Mr. Lang was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders in...

24 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

(e) As previously disclosed, Halozyme Therapeutics, Inc. (“the Company”) announced a transition plan in which Nicole LaBrosse, Senior Vice President, Chief Financial Officer will continue to serve as the Company’s Chief Financial Officer...

12 Nov 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

INDENTURE, dated as of November 12, 2025, between Halozyme Therapeutics, Inc., a Delaware corporation, as issuer (the “Company”), and The Bank of New York Mellon Trust Company, N.A., not in its individual capacity but solely as trustee, ...

07 Nov 2025 8-K: Other Events

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of$650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support